Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miguel Torralba

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
AIDS (London, England)|March 10, 2026
Determinants of long-acting cabotegravir plus rilpivirine discontinuation in real-world HIV care: insights from the RELATIVITY cohortJesús Troya, María Luisa Montes, María José Galindo, et al.
AIDS (London, England)|November 3, 2025
Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohortLuis Buzón, José I Bernardino, María José Galindo Puerto, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 30, 2022
Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical TrialRocío Montejano, Fernando de la Calle-Prieto, María Velasco, et al.
The Lancet. HIV|June 9, 2025
Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trialPablo Ryan, José L Blanco, Mar Masia, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 25, 2024
A Phase III Randomized Controlled Trial of Plitidepsin, a Marine-Derived Compound, in Hospitalized Adults With Moderate COVID-19Pedro Landete, Olga-Adriana Caliman-Sturdza, Jose A Lopez-Martin, et al.
Medicina Clinica|December 19, 2002
[Retrospective epidemiological study on the durability of the treatment of HIV infection or AIDS in Spain]José Ramón Arribas López, Susana Sanz Baena, Susana Hernández Albujar, et al.
Medrxiv : the Preprint Server for Health Sciences|June 2, 2021
Plitidepsin has a positive therapeutic index in adult patients with COVID-19 requiring hospitalizationJosé F Varona, Pedro Landete, Jose A Lopez-Martin, et al.
Life Science Alliance|January 11, 2022
Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19Jose F Varona, Pedro Landete, Jose A Lopez-Martin, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|April 9, 2016
Executive summary: Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015José Antonio Iribarren, Rafael Rubio, Koldo Aguirrebengoa, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|March 16, 2016
Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015José Antonio Iribarren, Rafael Rubio, Koldo Aguirrebengoa, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
AIDS (London, England)|March 10, 2026
Determinants of long-acting cabotegravir plus rilpivirine discontinuation in real-world HIV care: insights from the RELATIVITY cohortJesús Troya, María Luisa Montes, María José Galindo, et al.
AIDS (London, England)|November 3, 2025
Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohortLuis Buzón, José I Bernardino, María José Galindo Puerto, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 30, 2022
Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical TrialRocío Montejano, Fernando de la Calle-Prieto, María Velasco, et al.
The Lancet. HIV|June 9, 2025
Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trialPablo Ryan, José L Blanco, Mar Masia, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 25, 2024
A Phase III Randomized Controlled Trial of Plitidepsin, a Marine-Derived Compound, in Hospitalized Adults With Moderate COVID-19Pedro Landete, Olga-Adriana Caliman-Sturdza, Jose A Lopez-Martin, et al.
Medicina Clinica|December 19, 2002
[Retrospective epidemiological study on the durability of the treatment of HIV infection or AIDS in Spain]José Ramón Arribas López, Susana Sanz Baena, Susana Hernández Albujar, et al.
Medrxiv : the Preprint Server for Health Sciences|June 2, 2021
Plitidepsin has a positive therapeutic index in adult patients with COVID-19 requiring hospitalizationJosé F Varona, Pedro Landete, Jose A Lopez-Martin, et al.
Life Science Alliance|January 11, 2022
Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19Jose F Varona, Pedro Landete, Jose A Lopez-Martin, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|April 9, 2016
Executive summary: Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015José Antonio Iribarren, Rafael Rubio, Koldo Aguirrebengoa, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|March 16, 2016
Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015José Antonio Iribarren, Rafael Rubio, Koldo Aguirrebengoa, et al.
Pageof 8